Clinical trial
Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant…
NCT00110188 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00110188 |
|---|---|
| Title | Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017) |
| Official title | A Phase II Study of the Efficacy and Safety of AP23573 in Patients With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC) |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Collaborators | Ariad Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | ridaforolimus |
| Enrollment | 39 |
| Start date | May 1, 2005 |
| Primary completion | Apr 1, 2007 |
| Completion | Aug 1, 2007 |
| First posted | May 5, 2005 |
| Last update posted | Nov 20, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: